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Abstract
Background: Claudin-low breast carcinoma represents 19% of all breast cancer cases and is characterized by an
aggressive progression with metastatic nature and high rates of relapse. Due to a lack of known specific molecular
biomarkers for this breast cancer subtype, there are no targeted therapies available, which results in the worst
prognosis of all breast cancer subtypes. Hence, the identification of novel biomarkers for this type of breast cancer
is highly relevant for an early diagnosis. Additionally, claudin-low breast carcinoma peptide ligands can be used to
design powerful drug delivery systems that specifically target this type of breast cancer.
Methods: In this work, we propose the identification of peptides for the specific recognition of MDA-MB-231, a cell
line representative of claudin-low breast cancers, using phage display (both conventional panning and BRASIL).
Binding assays, such as phage forming units and ELISA, were performed to select the most interesting peptides
(i.e., specific to the target cells) and bioinformatics approaches were applied to putatively identify the biomarkers to
which these peptides bind.
Results: Two peptides were selected using this methodology specifically targeting MDA-MB-231 cells, as
demonstrated by a 4 to 9 log higher affinity as compared to control cells. The use of bioinformatics approaches
provided relevant insights into possible cell surface targets for each peptide identified.
Conclusions: The peptides herein identified may contribute to an earlier detection of claudin-low breast
carcinomas and possibly to develop more individualized therapies.
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Background
Breast cancer is the most frequent cancer among
women, representing 25% of all cancer cases, and the
most frequent cause of cancer death in less developed
countries and the second in developed regions [1].
Breast cancer has long been recognized as a heteroge-
neous disease [2], challenging an effective detection, diag-
nosis and treatment. Initially based on morphological
observations, this heterogeneity has been confirmed by
high-throughput methods such as molecular profiling
with microarrays. These have allowed the identification of
specific biomarkers whose presence or absence enable
distinguishing breast cancers into different subtypes.
The currently accepted biomarkers include the estro-
gen (ER), progesterone (PR) and human epidermal
growth factor 2 (HER2) receptors [3], diving breast
cancer into the following subtypes: luminal A (ER+,
PR+/−, HER2−), luminal B (ER+, PR+/−, HER2+), HER2
(ER−, PR−, HER2+), basal-like (ER−, PR−, HER2−) and
claudin-low (ER−, PR−, HER2−) [4, 5]. The claudin-
low subtype was initially clustered together with the
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basal-like but the presence of unique features (e.g.,
downregulation of claudin-3 and claudinin-4 and the
low expression of proliferation marker Ki67) led to its
own subtype [6, 7].
Each cancer subtype has a different prognosis and
treatment response [4]. Luminal A and luminal B sub-
types, characterized by the presence of ER, are com-
monly treated with hormone therapy with a good overall
outcome; HER2 subtype, with the presence of HER2 can
be treated with anti-HER2 monoclonal antibody therapy;
but the basal-like and claudin-low subtypes, due to the
absence of expression of a recognizable therapeutic
target, lack targeted therapeutic options [8, 9]. Unfortu-
nately, these represent about 19% of all breast cancer
cases and include those with worst prognosis due to its
aggressive and metastatic nature and high rates of relapse
[10]. The identification of specific molecular biomarkers
for these subtypes would be a valuable contribution to a
more precise diagnosis and to the development of individ-
ualized therapies to different molecular subgroups.
However, the quest for molecular biomarkers specific
for cancer cells remains a challenge due to the lack of
affinity reagents that can specifically bind to unique mo-
lecular targets on the surface of the these cells. The iso-
lation and identification of such reagents is vital for
clinical applications in cancer diagnosis and therapy
[11]. Evolutionary screening techniques, such as phage
display [12], have demonstrated incredible capacity to
identify affinity reagents for a wide variety of targets
(proteins, nucleic acids, inorganic materials, cells, among
others) [13, 14]. In fact, phage display has already been
used to generate recombinant antibody fragments that
specifically recognize breast cancer subpopulations [15],
as well as cell-targeting peptides for SK-BR-3 breast can-
cer cells [16]. In addition, phage display does not require
prior knowledge of the cell surface, has low costs, and
the cell-specific peptides identified typically present low
immunogenicity [17, 18].
In this work, we used phage display to identify pep-
tides specifically recognizing the claudin-low breast
cancer cell line MDA-MD-231. The identification of
such peptides could open new perspectives for the devel-
opment of targeted therapies against this specific breast
cancer subtype. Binding assays were performed to select
the most specific peptides and a bioinformatics analysis
was implemented to evaluate their potential targets on
the cell surface.
Methods
Library diversity and preparation
The M13KE phage and its host, Escherichia coli ER2387,
were obtained from New England Biolabs (NEB). Two
different libraries of M13KE were used, namely a home-
made 7-mer library and a commercial 12-mer library
from NEB (E8110S). The construction of the 7-mer li-
brary was performed as described in [19], using primers
5′–CATGCCCGGGTACCTTTCTATTCTC–3′ and
5′– (NNN)7AGAGTGAGAATAGAAAGGTACCCG
GG–3′ and digested as in the protocol for M13KE
DNA insertion (7.2 kb).
Cell line and culture
The human cancer cell lines MDA-MB-231 (claudin-low
subtype), SK-BR-3 (HER2 subtype), Hs 578 T (basal-like
subtype) and MDA-MB-435 (melanoma [20]) were
kindly provided by the Institute of Molecular Pathology
and Immunology at the University of Porto (IPA-
TIMUP). The human mammalian cell line MCF-10-2A
(ATCC CRL-10781) is non-tumorigenic and was used as
a control. MDA-MB-231, SK-BR-3, Hs 578 T, and MDA-
MB-435 cells were routinely cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM, Biochrom) supplemented
with 10% (v/v) fetal bovine serum (FBS, Biochrom) and
1% (v/v) penicillin-streptomycin (Biochrom). MCF-10-2A
cells were grown in a 1:1 solution of DMEM and HAM’s
F-12 medium supplemented with 5% horse serum (Merck
Millipore), 20 ng.mL−1 epidermal growth factor (Merck
Millipore), 100 ng.mL−1 cholera toxin (Sigma-Aldrich),
0.01 mg.mL−1 insulin (Sigma-Aldrich), 500 ng.mL−1
hydrocortisone, 95% (Sigma-Aldrich) and 1% penicillin-
streptomycin. All cell lines were cultured at 37 °C and 5%
CO2. Subculturing was performed at 80% confluence, by
washing the monolayer with sterile phosphate buffered-
saline (PBS), pH 7.4, without Ca2+ and Mg2+, and detach-
ing the cells with Trypsin/EDTA solution 0.05%/0.2%
(w/v) (Biochrom). The cell suspension was centrifuged
at 250 × g for 7–10 min and the cell pellet was resus-
pended on fresh growth medium, counted and split ac-
cording to the experimental needs.
Panning experiments – conventional selection versus
BRASIL
Both conventional phage display and BRASIL [21]
methods were used to compare their performance in the
selection of a peptide specific to the MDA-MD-231 cells.
The BRASIL method is in principle faster than the conven-
tional panning and by using counter-selection it reduces
the number of false positives. However, this methodology
uses cells in suspension, which may hide surface receptors
that are only available in the adherent state. The panning
experiments with both methodologies were performed
equally for the 7-mer and the 12-mer libraries. The experi-
mental setting can be seen in Additional file 1: Table S1.
Conventional selection (surface panning procedure – direct
target coating)
One mL of MDA-MB-231 cell suspension at a concen-
tration of 106 cells.mL−1 was added to a 6-well
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microtiter plate and incubated overnight at 37 °C in a
5% CO2 humidified incubator. The medium was then re-
moved and the wells completely filled with blocking buf-
fer (0.1 M NaHCO3 (pH 8.6, Sigma), 5 mg.ml
−1 Bovine
Serum Albumin (BSA) (Sigma) solution IgG-free, low
endotoxin suitable for cell culture (Sigma). After an in-
cubation of 1 h at 4 °C, the blocking solution was dis-
carded and the wells washed 6 times with Tris Buffered
Saline with Tween-20 (TBST, TBS with 0.1% (v/v)
Tween-20) (Sigma-Aldrich). One mL of a 100-fold dilu-
tion in TBST of the library (7-mer or 12-mer) (1x1011
for a library with 2x109 clones) was added to the coated
wells and rocked gently for 60 min at 4 °C (to limit
phage internalization). The non-binding phage was dis-
carded and the wells were washed 10 times with TBST.
The bound phage was then eluted with 750 μL of PBS
1x (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and
1.8 mM KH2PO4), and rocked gently for 60 min at 4 °C.
The eluate was transferred to a microcentrifuge tube
and the titer was determined using the double layer agar
technique [22] in LB plates containing 100 μM IPTG
and 20 μg.mL−1 X-gal, counting the blue colonies. The
remaining eluate was amplified by adding the eluate to
20 mL early-log ER2738 culture and incubating with vig-
orous shaking for 4.5 h at 37 °C. The culture was spun
at 12,000 × g for 10 min at 4 °C, and the supernatant
was transferred to a fresh tube and re-spun. The upper
80% of the supernatant was transferred to a new tube
and the phage was precipitated with 1/6 volume of 20%
polyethylene glycol (PEG) 8000/2.5 M NaCl for at least
2 h at 4 °C. This solution was centrifuged at 12,000 × g
for 15 min at 4 °C, the supernatant was discarded and
the phage pellet was suspended in 1 mL TBS. PEG/NaCl
precipitation was repeated and the final pellet suspended
in 200 μL TBS. The titer was determined as previously
described. The whole process was repeated for a total of
8 rounds of panning.
A control panning experiment was carried out using
streptavidin as the target, including 0.1 μg.mL−1 streptavi-
din in the blocking solution. The bound phage was eluted
with 0.1 mM biotin in TBS for at least 30 min. After 3
rounds of enrichment/amplification, the consensus se-
quence for streptavidin-binding peptides was assessed to
confirm the inclusion of the motif His-Pro-Gln.
BRASIL
A biopanning protocol was used as described in [21].
Briefly, MDA-MB-231 cells.mL−1 were collected, centri-
fuged (250 × g, 10 min) and the pellet suspended in
1 mL of complete DMEM medium, containing 1% (w/v)
BSA. The solution was centrifuged and this step re-
peated 3 times; the cells were re-suspended in complete
growth medium containing 3% (w/v) BSA solution and
kept on ice. Ten μL of the phage library (7-mer or 12-
mer) were added to the previous cell suspension and in-
cubated on ice for 4 h. A bubble of 300 μL PBS was
formed on a non-miscible organic phase (cyclohexane:-
dibutyl phthalate (1:9, v/v, Sigma)), and 200 μL of the
cell suspension incubated with the phage library were
gently inserted into the bubble. After centrifuging at
10,000 × g for 10 min, the pellet was recovered and
washed with 50 μL Tris–HCl (10 mM, pH 9.5). Eluted
phages were amplified between rounds using E. coli
ER2738, purified and concentrated with 20% PEG 8000/
2.5 M NaCl. Phage titer was determined as described
above. The amplified phages were used for additional
rounds of biopanning in a total of eight. A final round of
counter-selection with MCF-10-2A cells (non-tumori-
genic) was performed, differing from the previous
rounds in the fraction collected, which in this case was
the aqueous phase containing the phages that did not
bind to the control cells.
Preliminary analysis of the specificity and selectivity of a
phage pool
Flow cytometry analysis
To characterize pool specificity and selectivity, the last
round of the 12-mer phage pool from conventional pan-
ning was conjugated with Alexa 488 and analyzed using
flow cytometry to evaluate the binding to MCF-10-2A
(control, non-tumorigenic cells), MDA-MB-231, MDA-
MB-435, SK-BR-3 and Hs 578 T cell lines. Briefly, 1×105
cells were harvested, washed in PBS and blocked using
PBS with 3% BSA at 4 °C for 1 h. Subsequently, the cells
were washed with PBST 1× (PBS with 0.1% (v/v) Tween-
20) and were incubated with 100 μL of fluorescent phage
particles. The cells were rinsed again with PBST 1x and
finally resuspended in 200 μL of PBS for flow cytometry
analysis using a EC800™ flow cytometer analyzer (Sony
Biotechnology Inc.) counting 20,000 events.
Tissue section analysis
For immunohistochemical analysis, serial sections of
paraffin-embedded 231 mammary cancer tissue sections,
kindly provided by Dr. João Nuno Moreira (CNC, Coim-
bra, Portugal), were treated as described in [23]. To
maximize antibody binding, antigen retrieval was per-
formed by heating the slides in 10 mM sodium citrate
buffer (pH 6.0) at 95 °C for 20 min and the slow cooling
at room temperature in the same buffer for about
20 min. Tissues were maintained humid at all time. Tis-
sue sections were blocked using a 5% BSA solution and
were incubated at room temperature for 30 min. Immu-
nostaining was performed by adding 100 μL of the last
round of the 12-mer phage pool (109 PFUs.mL−1) to the
tissue overnight at 4 °C [24, 25]. Sections were washed 4
times in TBST 1x for 5 min and 100 μL of the primary
antibody rabbit anti-fd bacteriophage (working dilution
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of 1:5000 in BSA 1%), was added and incubated at 4 °C
overnight. Sections were washed several times with
TBST 1x and were challenged with the fluorescein iso-
thiocyanate (FITC)-labelled goat anti-rabbit IgG second-
ary antibody (working dilution of 1:40 in 1% BSA) for
2 h at room temperature. After additional washing of
the sections with TBST buffer, sections were counter-
stained with 4′, 6 - diamidino-2-phenylindole (DAPI,
Vector Laboratories) for nuclear labelling and were
mounted with Vectashield® mounting medium (Vector
Laboratories). The tissue sections were allowed to dry
for 1 h at room temperature in the dark and were sealed
with nail polish. Images of the slides were captured
using an Olympus BX51 microscope incorporated with a
high-sensitivity camera Olympus DP71 with 60×
magnification.
Selection and screening of cell-specific peptides
Preparation of individual clones for peptide analysis
Single-stranded DNA (ssDNA) was prepared according
to the standard protocol described in [19], using iodide
buffer (10 mM Tris–HCl, 1 mM EDTA and 4 M NaI
(Sigma-Aldrich), pH 8.0) and ethanol precipitation. The
DNA pellet was suspended in 30 μL TE buffer (10 mM
Tris–HCl, 1 mM EDTA, pH 8.0), quantified using Nano-
drop 1000 and confirmed by 2% gel electrophoresis in
SGTB (GRISP) buffer 1× at 200 V for 30 min.
PCR and confirmation electrophoresis
The insert sizes of the individual clones, as well as of the
complete library were assessed by PCR using the forward
primer 5′-TTAACTCCCTGCAAGCCTCA-3′ and the
reverse primer 5′-CCCTCATAGTTAGCGTAACG -3′.
PCR reactions were carried out using KAPA Taq poly-
merase in 20 μl reaction volume, containing 2 μL of
phage DNA. The PCR conditions were the following:
25 cycles of denaturation at 95 °C for 30 s; annealing in
the temperatures range from 45 to 70 °C, for 30 s; and
extension at 72 °C for 30 s. Amplification was confirmed
by 2% gel electrophoresis in SGTB buffer 1× at 200 V
for 30 min.
DNA sequencing and insert analysis
The DNA products obtained were prepared for sequen-
cing using Illustra ExoProStar 1-Step (GE Healthcare) and
sent to Macrogen Inc. service using the M13-PIII sequen-
cing primer 5′- TTAACTCCCTGCAAGCCTCA-3′, pro-
vided with the Ph.D.12-mer library kit for forward reading
and the primer 5′ -CCCTCATAGTTAGCGTAACG-3′
for reverse reading. The Vector NTI Advance 11.5.0 soft-
ware (Invitrogen – Life Technologies) was used for the
analysis of correct insertion of the peptides taking into
account that the displayed peptides are expressed at the
N-terminus of pIII, followed by a short spacer (Gly-Gly-
Gly-Ser) and then the wild-type pIII sequence.
Binding assays
Binding assay with counting of blue colony forming units
(pfu)
The binding of the peptides displayed on M13KE phage
was evaluated following a procedure similar to the con-
ventional panning. First, the individual clones were amp-
lified, centrifuged at 12,000 × g for 10 min at 4 °C, and
the supernatant used for phage concentration with 20%
PEG 8000/2.5 M NaCl. Phages were suspended in 50 μL
TBS and the titer was determined using the double layer
agar technique. Then, 1 mL of MDA-MB-231 cells at a
concentration of 106 cells.mL−1 was added to a 6-well
microtiter plate and incubated overnight at 37 °C and
5% CO2. MDA-MB-435 cells were used as a negative
control in the same conditions. The cell medium was re-
moved and the wells were washed 6 times with TBST.
Then, 1 mL of each M13KE-peptide suspension, at a
concentration of 1×1011 PFU.ml−1 was added to the
wells and incubated for 60 min at 4 °C. The non-binding
phage was discarded and the wells were washed 10 times
with TBST. The bound phages were then eluted with
750 μL of PBS 1x and rocked gently for 60 min at 4 °C.
The eluate was collected and the titer was determined
using the double layer agar technique in IPTG/X-gal
plates.
ELISA with direct target coating
ELISA was performed to rapidly determine whether a
selected phage clone binds the target, using the protocol
described in the NEB Phage Display manual [19]. For
each clone to be characterized, one row of coated (with
target cells) and uncoated wells were used. Plates were
read at 405 to 415 nm (Promega Glomax 20/20 lumin-
ometer) and the signals (RLUs) obtained with and with-
out target protein (cells) were compared.
Bioinformatics analysis
Library analysis
Sequence similarities between the peptides obtained in
this work and peptides reported in the literature targeting
cancer cells (see Additional file 2: Table S3) were scored
using Blosum45 matrices and the Needleman-Wunsch al-
gorithm as implemented by the pairwise alignment func-
tion from the R Biostrings package version 2.38.2 [26].
The symmetric matrix containing the scores for the pair-
wise sequence alignments, SC(i,j), was converted into a
similarity matrix taking into account the background
values for each sequence following a procedure similar to
the Context Likelihood of Relatedness (CLR) algorithm
used to detect spurious association in transcriptional or
metabolite association networks [27, 28]. Briefly, the
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likelihood of SC(i,j) is estimated using a null model given
by considering all the alignment scores involving inde-
pendently sequences i and j, SCi and SCj, respectively. The
background score is approximated as a joint normal distri-
bution with SCi and SCj treated as independent variables.
The final form of the likelihood estimate is:
f zi; zj
  ¼
ﬃﬃﬃﬃ
z2i
q
þ z2j ð1Þ
where
zi ¼ max 0; SC i; kð Þ− μi
σ i
 
ð2Þ
and μi and σi are, respectively, the mean and the stand-
ard deviation of the empirical distribution of SC(i, k)
with k = 1,…,n, and n the total number of considered se-
quences. The similarity estimate is then a matrix with
entries f(zi, zj). The similarity estimate was normalized,
through dividing by its highest values, to use in Multidi-
mensional scaling (MDS) plots, clustering and heatmap
reconstruction using the R gplots library [29].
Docking studies
Known biomarkers of breast cancer were selected from
a literature and databases search (see Additional file 3:
Table S4). The biomarkers found were retrieved through
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
for pathways and function analysis of biomarkers, Uni-
prot for protein characterization and amino acid se-
quences, GenBank for gene sequences, and Protein Data
Bank (PDB) for tri-dimensional protein structures [30].
When protein structures were not available, they were
predicted using the PHYRE2 software [31] and the
peptide structures were predicted using PEPstrMOD
[32, 33]. The resulting pdb files were used in a protein-
peptide analysis performed using ClusPro 2.0 [34, 35] in
all available models, by the peptide sequences identified
by phage display against the tri-dimensional structures
of the breast cancer biomarkers. Weighted score (E) was
obtained by:
E ¼ 0:40Erep þ −0:40Eatt þ 600Eelec þ 1:00EDARS
Balanced coefficientsð Þ
ð3Þ
E ¼ 0:40Erep þ −0:40Eatt þ 1200Eelec þ 1:00EDARS
Electrostatic‐favored coefficientsð Þ
ð4Þ
E ¼ 0:40Erep þ −0:40Eatt þ 600Eelec þ 2:00EDARS
Hydrophobic‐favored coefficientsð Þ
ð5Þ
E ¼ 0:40Erep þ −0:10Eatt þ 600Eelec þ 0:00EDARS
Vand der Waals and Electrostatic coefficientsð Þ
ð6Þ
where the lowest energy state represents the highest
binding. The tri-dimensional model structures obtained
were visualized using UCSF Chimera version 1.10.2 [36].
Alignments were scored using Blosum45, 50 and 62
matrices.
Statistical analysis
GraphPad Prism 5.03 (GraphPad Software, Inc.) was
used for statistical analysis of the data. The significance
of differences was evaluated using the One-way ANOVA
with Tukey’s Multiple Comparison Test, considering a
significance level of 95%.
Results
Identification by phage display of a peptide that
recognizes the breast cancer cell line MDA-MB-231
Phage display search of ligands specific for breast cancer
cell surface receptors, as any other variety of targets, is a
balance between the affinity to the target and its fre-
quency on the library pool. Therefore, the library hetero-
geneity is a critical step for the success of panning
experiments. In this study, we initially used a commer-
cial 12-mer library aiming to isolate highly specific pep-
tides directed against potential biomarkers present on
the cell surface of MDA-MB-231 cells. For this purpose,
we used the conventional phage display methodology.
The phage pool of the last round of phage display was
subjected to preliminary assays against several cell lines
(MDA-MB-231, MCF-10-2A, SK-BR-3, Hs 578 T and
MDA-MB-435) using flow cytometry to evaluate its
specificity for MDA-MB-231 cells. The flow cytometry
results, presented in Additional file 4: Figure S1, clearly
indicate the selectivity of the phage pool towards MDA-
MB-231 cells, with statistical significance as compared
to the remaining cell lines evaluated. Then, this prelim-
inary analysis was refined to study the interaction of the
phage pool with the MDA-MB-231 cells by immunohis-
tochemistry. Additional file 5: Figure S2 demonstrates
binding of the phage pool to MDA-MB-231 tissue
sections (identified by green fluorescence in Additional
file 5: Figure S2B), in contrast to the wild type M13KE
phages, which exhibit no staining (Additional file 5:
Figure S2A), thus clearly suggesting the capacity of the
peptides selected by phage display techniques to interact
with the target cells.
With these initial results we could confirm the possi-
bility of obtaining specific and selective peptides for the
MDA-MB-231 cell line and so, we enlarged the study
using an additional phage display library, containing only
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7 amino acids (7-mer library), as well as a more recently
developed phage display methodology, Biopanning and
rapid analysis of selective interactive ligands (BRASIL). A
library of smaller peptides may offer an advantage over the
12-mer library on the strength of binding of the peptides
selected. Additionally, BRASIL presents the advantages of
being faster and using counter-selection (to remove pep-
tides that bind to targets present on other cells), but can
be limited by the use of suspended cells, potentially hiding
surface receptors only present in the adherent state.
For each phage display methodology and library, eight
rounds of panning were performed and the peptides ob-
tained from the last panning round of each experimental
set (details provided in Additional file 1: Table S1) are pre-
sented in Table 1. Also, the consensus sequence with the
respective overall percentage was determined (Table 1).
Conventional phage display and BRASIL methodolo-
gies resulted in similar consensus sequences. In fact, for
the 7-mer library the sequence is identical (PRLNVSP),
and for the 12-mer library only the first two amino acids
are different (TTFNSFGRVRIE for the conventional
method and WWFNSFGRVRIE for BRASIL). On the
other hand, comparing the two libraries herein used, the
consensus peptides obtained are very different. Further-
more, the overall percentage of consensus is higher for
the commercial 12-mer library (86 %, 87%) than for the
home-made 7-mer library (70 %, 60%).
Binding assays
Peptides 1.3(7/52) (PRWAVSP), 5.3(14/45) (WWFNSF
GRVRIE), 5.3(19/45) (WWFFSFGRVRIE), 6.2(8/17) (TTE
YSFGRTSTL) and 6.2(9/17) (DTFNSFGRVRIE) were
Table 1 Conventional and modified BRASIL enrichment results based on binding affinity to the breast cancer MDA-MB-231 cell line
and a counter selection with the non-tumorigenic MCF-10-2A cell line with the 7-mer and 12-mer libraries
Method 7-mer library 12-mer library
Phage clone Sequence Phage clone Sequence
Conventional 3.1 (5/27) PRLNTSP 6.2 (1/17) TTFNSFGRVAIE
3.1 (6/27) PTLDVAP 6.2 (2/17) TTFCSFGRVRIE
3.1 (8/27) PQLNVSP 6.2 (3/17) TTFNSFGRVRIE
3.1 (9/27) PGAQVSP 6.2 (4/17) TTFNSFGRVHWE
3.1 (10/27) PRTNVAP 6.2 (5/17) TTFNSFGKVRIE
3.1 (11/27) PRKTVSP 6.2 (7/17) TTYNSFGRVRIE
3.1 (12/27) PAMNVSP 6.2 (8/17) TTEYSFGRTSTL
3.1 (13/27) PQENASP 6.2 (9/17) DTFNSFGRVRIE
3.1 (19/27) PSLNVSP 6.2 (10/17) TTFNSFGRVRIQ
3.1 (20/27) ARLNVAP 6.2 (12/17) TTFNSFGRVRIE
3.1 (21/27) TMLMVRP 6.2 (13/17) TNFNDFKRVRGE
3.1 (22/27) ARLNTQP 6.2 (14/17) TTFSSFGRVRIG
3.1 (23/27) PMMAVAP 6.2 (15/17) TTFNSNGRVWIE
3.1 (26/27) PRLNVSP 6.2 (16/17) TTFNSFGRVRGG
3.1 (27/27) PRLNVSP 6.2 (17/17) TTFNSFYRVRIE
Consensus (overall %) PRLNVSP (70%) Consensus (overall %) TTFNSFGRVRIE (86%)
BRASIL 1.3 (2/52) PRQNQSP 5.3 (1/45) WWFNSFGRVRIE
1.3 (3/52) QLKNVTP 5.3 (3/45) WAFNSFGRVRIE
1.3 (5/52) PRLNVAT 5.3 (5/45) WWFNKFGKVRIE
1.3 (6/52) PRLNVTT 5.3 (14/45) WWFNSFGRVRIE
1.3 (7/52) PRWAVSP 5.3 (16/45) IWFNSFFRVRIE
1.3 (8/52) PRLNHSP 5.3 (19/45) WWFFSFGRVRIE
1.3 (10/52) PQMTAMP 5.3 (20/45) GWFNSFGRWSWL
1.3 (11/52) MFLNGAP 5.3 (23/45) WWFNSFGRVRIE
1.3 (15/52) TRLQVSP 5.3 (43/45) WWFFSFGRWSWL
1.3 (19/52) WRMAHSP 5.3 (45/45) WWFNSFGRVRIE
Consensus (overall %) PRLNVSP (60%) Consensus (overall %) WWFNSFGRVRIE (87%)
Bold words represent the consensus (overall %) for the two methods
Nobrega et al. BMC Cancer  (2016) 16:881 Page 6 of 14
selected among those identified by phage display to assess
in vitro for their binding affinity to MDA-MB-231 (clau-
din-low breast cancer subtype), by incubation of the cells
with M13KE phages containing each peptide in analysis.
The melanoma MDA-MB-435 cells were used as a nega-
tive control to evaluate the specificity of the peptides for
the breast cancer MDA-MB-231 cells. The results, pre-
sented as the ratio between the concentration of phages
bound to each cell line and the initial phage concentration
used, are shown in Fig. 1.
The phages displaying the selected peptides have a
higher binding affinity to MDA-MB-231 cells than to
MDA-MB-435 cells, with the differences ranging from
0.55 (corresponding to 6 logs, for peptides 5.3(14/45), se-
quence WWFNSFGRVRIE and 5.3(19/45), sequence
WWFFSFGRVRIE) to 0.80 (9 logs, for peptides 1.3(7/52),
sequence PRWAVSP and peptide 6.2 (9/17) sequence
DTFNSFGRVRIE), with the latter two demonstrating the
most promising results in terms of specificity and binding
strength.
Enzyme-linked immunosorbent assays (ELISA) were
performed with the selected peptides against MDA-MB-
231 cells. MDA-MB-435 cells were used as a negative
control and streptavidin as a positive control (using an
M13KE phage displaying affinity peptides towards strep-
tavidin). Results were read in a luminometer and the
relative light units (RLUs) obtained are shown in Fig. 2.
The ELISA assays are in good agreement with the re-
sults obtained from the binding assays described above
(Fig. 1), with all peptides showing higher affinity to the
MDA-MB-231 cells than to the MDA-MB-435 cells. The
differences observed between the two cell lines range
from 3 to 4 logs.
Library analysis
The peptides obtained in this work were compared to
previously reported peptides (specific to breast cancer
cells) to assess possible similarities. This was performed
using pair-wise sequence alignments to prevent the bias
towards the discovery of consensus sequence obtained
when using multiple sequence alignments. Blosum45, 50
and 62 were used and compared, with the Blosum45
matrix being chosen to score the alignments since it is
more adequate to score divergent sequences. An initial
analysis demonstrated a high impact of sequence length
on the similarity computation (see Additional file 6:
Figure S3). Therefore, to consider the local background
of each sequence regarding the alignment score, the CLR
algorithm was adapted to this context. This algorithm has
been used successfully to take the local background into
account when assessing similarities between gene expres-
sion profiles or metabolite concentrations [27, 28].
The multidimensional scaling of the peptides can be
seen in Fig. 3, where graphical distances between the item
represents the (dis)similarities between the sequences.
The algorithm places the newly identified sequences in
the outskirts of the figure, indicating an average low simi-
larity shared with previously identified peptides.
The similarities between all sequences were illustrated
in a heatmap (Additional file 6: Figure S3). Even though
the local context of each sequence has been considered,
there was still a prevalence of association between
Fig. 1 Binding assays of selected peptides against MDA-MB-231 and MDA-MB-435 cell lines, using an initial phage concentration of 1×1011
PFUs.mL.1. Results are expressed as the ratio between the concentration of phages bound to the cells (output) and the initial phage concentration
used (input)
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sequences of similar length. Therefore, to fully consider
the effect of this bias, separated heatmaps for the 7-mer
(Fig. 4) and 12-mer peptides (Fig. 5) were built only con-
sidering peptides of the same length. Results show that
indeed the newly identified peptides are far (in sequence
space) from those previously reported.
Docking studies
A structural bioinformatics approach was implemented
to identify potential targets of the peptides in the MDA-
MB-231 cells. For this purpose, established biomarkers
present in breast cancer cells were retrieved from the lit-
erature using search engines such as PubMed (with
Fig. 2 Relative light units (RLUs) obtained for the selected peptides assessed by ELISA against MDA-MB-213 and MDA-MB-435 cell lines, as well as
against the control streptavidin, according to the New England BioLabs phage display manual
Fig. 3 Multidimensional scaling of the peptides identified in this work against MDA-MB-231 cells and previously reported peptides against breast
cancer cells. New7Br: 7-mer peptides obtained in this work using the BRASIL methodology; New7Conv: 7-mer peptides obtained in this work
using the conventional methodology; New12Br: 12-mer peptides obtained in this work using the BRASIL methodology; New12Conv: 12-mer
peptides obtained in this work using the conventional methodology; remaining peptides are grouped according to the breast cancer type
targeted (adenocarcinoma, invasive ductal carcinoma, ductal carcinoma, adenocarcinoma and invasive ductal carcinoma, adenocarcinoma and
colorectal carcinoma, and peptides with no available information)
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keywords “breast cancer biomarkers”, “MDA-MB-231
biomarkers”, “breast cancer surface markers”, “MDA-
MB-231 surface markers”, and from open source data-
bases (e.g., SurfaceomeDB). The proteins (biomarkers)
were challenged by rigid body docking with the peptides
using ClusPro 2.0. The results of the best docking model
are shown in Table 2 and the tri-dimensional representa-
tion can be seen in Fig. 6. Additional information about
energy values for all biomarkers is given in Additional
file 7: Table S2.
Peptides 1.3 (7/52) (PRWAVSP) and 6.2 (9/17)
(DTFNSFGRVRIE), which were found to have the best
selective binding to MDA-MB-231, seem to interact with
the biomarkers Metalloproteinase Inhibitor 1 (TIMP-1)
and Plasminogen activator inhibitor 1 precursor (PAI1),
respectively. The MDA-MB-231 biomarker β-actin, asso-
ciated with breast cancer metastasis [37], is also targeted
by two peptides, 5.3 (19/45) (WWFFSFGRVRIE) and 6.2
(8/17) (TTEYSFGRTSTL).
Discussion
Claudin-low breast cancer subtype is characterized by an
aggressive and highly metastatic nature that combined
with the absence of known specific molecular bio-
markers results in a very poor prognosis of therapeutic
success [8, 9]. The identification of peptides that could
specifically recognize this type of breast cancer may
open new perspectives for the development of targeted
therapies leading to improved prognosis. Herein, we ap-
plied a phage display methodology coupled with bio-
informatics analysis to identify a peptide specific for a
cell line representing the claudin-low breast carcinoma,
namely the MDA-MB-231 cell line.
In a first stage, a conventional panning methodology
and a commercial 12-mer M13KE library were used to
identify a specific peptide against the MDA-MD-231 cell
line. The phage pool obtained in the last round of selec-
tion was firstly evaluated by flow cytometry for specifi-
city and selectivity against MDA-MB-231 cells, as well
as cell lines from other important cancer subtypes MCF-
10-2A, SK-BR-3 and Hs 578 T) and the melanoma
MDA-MB-435 cell line (Additional file 4: Figure S1).
The results indicate a strongest affinity for the target
cells, but also a good binding to the MCF-10-2A and
SK-BR-3 cell lines. The lowest affinity was detected for
the MDA-MB-435 cells, which was expected since they
Fig. 4 Heatmap representation of the similarities between the 7-mer peptides identified in this work with those previously reported. New7Br: 7-mer
peptides obtained in this work using the BRASIL methodology; New7Conv: 7-mer peptides obtained in this work using the conventional methodology;
Previous: 7-mer peptides reported in previous studies
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Fig. 5 Heatmap representation of the similarities between the 12-mer peptides identified in this work with those previously reported. New12Br:
12-mer peptides obtained in this work using the BRASIL methodology; New12Conv: 12-mer peptides obtained in this work using the conventional
methodology; Previous: 12-mer peptides reported in previous studies
Table 2 Data from the best docking model of the phage-display peptides against breast cancer biomarkers: biomarker, type of
interaction, number of cluster members and lowest-energy weighted score (E)
Phage clone Best docking model
Breast cancer biomarkers Type of interaction a Cluster members b Lowest energy E c
Conventional
6.2 (8/17) β-Actin Hydrophobic-favoured 661 −1128.8
6.2 (9/17) Plasminogen activator inhibitor 1 Hydrophobic-favoured 741 −1046.5
BRASIL
1.3 (7/52) Metalloprotease inhibitor 1 Hydrophobic-favoured 595 −1127
5.3 (14/45) E-cadherin Electrostatic-favoured 443 −1106
5.3 (19/45) β-Actin Hydrophobic-favoured 600 −1696.6
a Coefficient weights of E formula are adapted for Balanced, Electrostatic-favored, Hydrophobic-favored or van der Waals and Electrostatic interactions
b ClusPro 2.0 ranks models by cluster size. 1000 rotation/translation combinations of lowest score are chosen from 70,000 rotations performed, and are clustered
together to find the ligand position with the most “neighbors” in 9 angstroms, becoming a cluster center and the neighbors the members of the cluster. A second
cluster center is obtained with the remaining rotations and so on. So the most members on the cluster, the most significant the result
c Weighted score is calculated according to formula E = 0.40Erep + −0.40Eatt + 600Eelec + 1.00EDARS (Balanced), E = 0.40Erep + −0.40Eatt + 1200Eelec + 1.00EDARS
(Electrostatic-favored), E = 0.40Erep + −0.40Eatt + 600Eelec + 2.00EDARS (Hydrophobic-favored), or E = 0.40Erep + −0.10Eatt + 600Eelec + 0.00EDARS (Van der Waals
and Electrostatic)
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were used in counter-selection. Afterwards, immuno-
histochemistry analysis of the phage pool against tis-
sue sections of the target cells (MDA-MB-231) was
carried out (Additional file 5: Figure S2), demonstrat-
ing the binding affinity of the pool for the target.
These initial results proved the feasibility of obtaining
a specific peptide targeting the MDA-MB-231 cells
using phage display approaches. To increase the pos-
sibility of identifying peptides with strong binding
affinities, an additional phage display methodology
(BRASIL) and a home-made 7-mer M13KE library
were included in this study.
The 7-mer and 12-mer libraries led to different con-
sensus sequences (Table 1). This indicates a strong influ-
ence of the library on the phage display results, which
was expected due to the difference in length of the pep-
tides (7 or 12 amino acids). Indeed, although the 7-mer
library is adequate for a biopanning strategy, it is more
useful for targets requiring binding elements concen-
trated in a short sequence of amino acids [38, 39]. In
turn, the 12-mer library may have an advantage if the
binding amino acids (which most of the times are less
than 12) are spread out over the peptide sequence [38,
40]. Moreover, the 12-mer library may also increase the
effective peptide diversity since each 12-mer peptide
contains 7-mer peptides with different flanking se-
quences [39]. However, due to the increased length of
the 12-mer peptides, it is possible that sequences with
multiple weak binding are selected instead of sequences
with few strong bindings [38]. Nevertheless, libraries of
both lengths have been successfully used for biopanning
experiments, as also observed herein.
Comparing the phage display methodologies, for the
7-mer library, both BRASIL and conventional phage dis-
play resulted in the same consensus sequence. However,
for the 12-mer library the consensus sequence differed
between the two methodologies in the first two amino
acids, perhaps because as explained above, these two
amino acids may not be relevant for the strength of
binding of the 12-mer peptide. However, these methods
- conventional panning and BRASIL - do not display a
significant difference. Since BRASIL is simple and faster,
it is possible to say that this method is preferable for
practical purposes [21].
Five peptides from the phage pools were selected to
evaluate their binding affinities through different experi-
mental assays. Both phage forming units (PFUs, Fig. 1)
and ELISA (Fig. 2) assays suggest that all peptides exhibit
specificity to the MDA-MB-231 cells with a lower binding
capacity to MDA-MB-435 cells, as expected since this
latter cell line was used in the counter-selection. These
differences were of up to 80% (corresponding to 9 logs) in
the PFUs assays (Fig. 1) and 4 logs in the ELISA assays
(Fig. 2). These differences of peptide affinity between tar-
get and non-target cells are in accordance with values pre-
viously reported for phage display studies identifying
peptides specific for other cancer cells, e.g., renal carcin-
oma A498 cells [41], breast cancer SKBR3 cells [42] and
ovarian cancer HO8910 cells [43]. Among the peptides,
1.3(7/52) (PRWAVSP) and 6.2(9/17) (DTFNSFGRVRIE)
Fig. 6 Tri-dimensional view of the peptides (red) docked to the respective biomarker (blue). a Peptide 1.3 (7/52) docked to Metalloproteinase
Inhibitor 1, b peptide 5.3 (14/45) docked to E- cadherin, c peptide 5.3 (19/45) docked to β-Actin. d peptide 6.2 (8/17) docked to β-Actin,
and e peptide 6.2 (9/17) docked to Plasminogen activator inhibitor 1. Images were obtained with Chimera version 1.10.2
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present the most promising results for targeted therapies
of claudin-low cancer subtype due to the higher binding
strengths and selectivity for the MDA-MB-231 cells.
Bioinformatics analysis (Table 2) indicate that peptides
1.3(7/52) (PRWAVSP) and 6.2(9/17) (DTFNSFGRVRIE)
specifically target TIMP-1 and PAI1, respectively, with
both biomarkers being related to breast cancer and to
MDA-MB-231 cells. TIMP-1 is often overexpressed in
many malignancies and is associated with increased
histological grade, lymph-node and distant metastasis
and decreased survival in breast cancer [44]. It is present
and overexpressed in the MDA-MB-231 cells but also in
Hs 578 T cells, with no expression on the remaining cell
lines evaluated [45]. Although TIMP-1 has been consid-
ered a potential target for prognosis and therapeutic
purposes, to our knowledge no specific peptide, anti-
body, aptamer or other molecule has been identified
against this protein. Hence, the peptide herein identified
represents a promising development for the establish-
ment of prognosis tools, as well as targeted therapies.
On the other hand, PAI1 is considered a prognostic
marker due to a strong correlation with tumor aggres-
siveness and poor clinical outcome in breast cancer [46].
It is highly expressed in MDA-MB-231 cells, but also on
MCF-10-2A and SK-BR-3 cells, exhibiting low levels of
expression on Hs 578 T and MDA-MB-435 cells, which
is somewhat in accordance with the preliminary flow cy-
tometry results (Additional file 4: Figure S1) obtained
for the phage pool from which the peptide 6.2(9/17) was
obtained. Several aptamers have been developed that
bind and inhibit PAI1, exhibiting potential therapeutic
applications as anti-metastatic agents [47, 48]. The pep-
tide here identified represents another alternative also
with therapeutic and prognosis potential.
From the bioinformatics analysis, it is also interesting to
note that peptides with different sequences (5.3 (19/45)
sequence WWFFSFGRVRIE, and 6.2 (8/17) sequence
TTEYSFGRTSTL) can exhibit affinities towards the same
target (in this case the MDA-MB-231 biomarker β-actin,
associated with breast cancer metastasis [37]), while simi-
lar peptides differing only in one amino acid have a differ-
ent target (e.g., 5.3 (14/45), sequence WWFNSFGRVRIE
targeting E- cadherin)). This indicates that not only the
amino acid sequence, but also the tri-dimensional con-
formation of the peptides influence the peptide interac-
tions with the cells.
Finally, the peptide 5.3 (14/45) (WWFNSFGRVRIE)
exhibited the highest affinity for a biomarker that is not
present in the MDA-MB-231 cells (E- cadherin) [49], al-
though showing a similar affinity for a MDA-MB-231
biomarker (α-1-antichymotrypsin) (see Additional file 7:
Table S2). This might explain the lowest selective affinity
of this peptide for MDA-MB-231 cells as demonstrated
in the binding studies.
All the peptides identified in this study were compared
with reported breast cancer specific peptides and no
similarities have been found (Figs. 3, 4, and 5), thus
strongly supporting their novelty.
Conclusions
In this work we identified new peptides specific for the
MDA-MB-231 cells, which is representative of the
claudin-low subtype of breast carcinomas, using phage
display aided by bioinformatics tools. The methodology
used together with the interpretation of phage display
results (peptide sequences) being aided by bioinformatics
approaches can be very useful to predict the potential
cell targets (biomarkers) and to isolate peptides that are
specific for the desired cells from those binding to other
cancer subtypes. The selected peptides, PRWAVSP and
DTFNSFGRVRIE, exhibit a strong binding to the MDA-
MB-231 cells and a good specificity as demonstrated by
the low binding to the MDA-MB-435 cells. Such pep-
tides can be a valuable contribute towards future clinical
applications through the development of more specific
and targeted therapeutic solutions against the claudin-
low breast cancer subtype.
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